Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
for Giant Cell Arteritis (GCA)
Drug: Tocilizumab
7 locations incl. Atlanta
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All·Age: 50+
Code: NCT07108387·Phase 2·Recruiting